WINDOSR, ONTARIO – May 6th, 2015
The Wealthy Biotech Trader, an Investment Newsletter focused on showing everyday Investors new opportunities in rapidly growing little-known Biotech stocks, would like to highlight several oncology (or cancer) focused biotech stocks providing investors with greatest opportunity for significant growth potential.
2015 has so far been the year of the biotech company and investors are presented with a growing list of potential investment opportunities. Here’s a look at four of the companies that have been stand-out so far this year and present investors with significant upside opportunity. All have witnessed strong developments operationally and have experienced a surge in investor interest.
Propanc Health Group Corporation (OTC: PPCH), a development stage healthcare company that is currently focused on developing new cancer treatments for patients suffering from pancreatic and colorectal cancer, leads a very interesting field of companies that are making significant progress in the oncology space.
Propanc recently announced the first set of results from its animal studies using its treatment called PRP. According to the company’s announcement, PRP is showing no adverse clinical signs at the maximum tolerated dose (MTD) in mice when administered by I.V injection. Propanc has concluded that the findings are significant, showing that PRP is safe and tolerable when administered intravenously at higher doses. Follow-up to this news should report on its efficacy, or simply how well PRP works on tumors.
The successful testing of PRP in animals paves the way for the next step in the process of bringing a safe and effective treatment solution to market. Indeed human clinical trials are an important measure for the growth potential of any biotech opportunity and so far Propanc looks poised to make the next big leap.
Since being featured in the NY Times Sunday Edition Magazine under Health Essentials: Cancer Prevention & Treatment, April 19th, Propanc has eclipsed both its first and second resistance levels. Trading at just a shave over 5 cents in a recent session, the company has shown that investor interest is rising steadily and confirms that PRP could be an effective treatment solution for cancer, showing remarkable progress.
Investors should pay close attention to the underlying infrastructure of Propanc’s leading treatments which, for the most part, are based on the company’s novel formulation that either involve or employ proenzymes – essential clinical components and inactive precursors of enzymes.
Of course, there are several other players in the oncology space providing investors with significant growth opportunity. Most notable is Galena Biopharma, Inc. (GALE), a company that recently completed enrollment in the NeuVax(TM) (nelipepimut-S) Phase 3 PRESENT (Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer with Low to Intermediate HER2 Expression with NeuVax Treatment) clinical trial. The news is significant because NeuVax(TM) is a first-in-class, HER2-directed cancer immunotherapy which is currently being evaluated for its efficacy in preventing the recurrence of breast cancer.
Considering that breast cancer is the most frequently diagnosed cancer in the US for women, progress being made on the ground by Galena is potentially life-saving news. The company which found support at $1.37 has once again put itself on the investing radar courtesy of healthy pullbacks. Currently the stock has a second resistance point of $1.41 and there’s a general belief that the strong sector news could be a catalyst for a potential breakout.
Unlike the previously mentioned two biotech companies, Aeterna Zentaris Inc. (AEZS) is on a more advanced path clinically. The company recently announced that the independent Data Safety Monitoring Board (DSMB) for its important late-stage study on zoptarelin doxorubicin has been given the go-ahead for the continued phase III clinical study for the treatment of women suffering from advanced metastatic endometrial cancer. Again, this development shines the light on the importance of the continued development of treatment for women affected by a plethora of cancers. Investors have treated Aeterna Zentaris with no less optimism and the stock has reached as high as 1.54 in the last 12 months.
Consolidation for Aeterna Zentaris has been pretty steady over the last few weeks where the stock has found support at around 54 cents. Incidentally, resistance at the upper level is currently 58 cents which suggests that at current levels investors who take action could be looking at a potential breakout opportunity.
Finally, investors looking for the best of breed in terms of biotech upside shouldn’t ignore the exploits of Threshold Pharmaceuticals Inc. (THLD). The developer of Evofosfamide (previously known as TH-302), an investigational hypoxia-activated prodrug, has announced intent to initialize phase II clinical trials for its newly acquired cancer candidate, TH-4000.
Threshold Pharmaceuticals licensed TH-4000 (formerly known as PR610 or Hypoxin) from the University of Auckland of New Zealand back in September 2014. The drug holds promise because when it enters the tumor cells, it diffuses to the hypoxic zone, in which the TH-4000 effector (TH-4000E) is selectively activated and blocks hypoxia-induced EGFR signaling and tumor cell survival. In a very basic sense, TH-4000 is able to help in combatting the survival of cancer-protracting EGFR.
Threshold Pharmaceuticals has enjoyed very strong consolidation below 4.00 but investors have enjoyed rallies as high as 5.41 in the last year. The stock is trading just above support of 3.42 and with resistance not very far north at 3.74, investors could be in line for another major delivery of profits on a potential breakout.
The biotech industry presents incredible growth potential for investors savvy enough to seize the opportunity today. Companies like Propanc Health Group Corporation (PPCH) are solid growth candidates as they combine the best of both worlds – solid fundamentals and very robust technicals.
The Wealthy Biotech Trader is researching several new trade ideas which have the makings for large market moves. Active traders are urged to follow our parent outlet, The Wealthy Venture Capitalist on social media to stay apprised. We are an anti-email media outlet, and as such will only be releasing our reports/ updates/ news through our Twitter and Facebook accounts, as well as newswire.
TO GET BREAKING NEWS FROM US:
Follow us on twitter: @Wealthy_VC
Like us on Facebook: www.facebook.com/WealthyVC
This report/release/profile is a commercial advertisement and is for general information purposes only. We are engaged in the business of marketing and advertising companies for monetary compensation unless otherwise stated below. The Wealthy Biotech Trader and its employees are not a Registered Investment Advisors, Broker Dealers or a member of any association for other research providers in any jurisdiction whatsoever and we are not qualified to give financial advice. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. The Wealthy Biotech Trader encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled through their website, news releases, and corporate filings, or is available from public sources and The Wealthy Biotech Trader makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. The Private Securities Litigation Reform Act of 1995 provides investors a ‘safe harbor’ in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be “forward looking statements”. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as “projects”, “foresee”, “expects”, “will”, “anticipates”, “estimates”, “believes”, “understands”, or that by statements indicating certain actions “may”, “could”, or “might” occur. Understand there is no guarantee past performance will be indicative of future results. Past Performance is based on the security’s previous day closing price and the high of day price during our promotional coverage.
Readers must visit our website at www.wealthyventurecapitalist.com in order to view our entire disclaimer which covers most of the risks, biases and liability releases to have a full understanding after reading this article.